MedTrace Logo

Registry for Adults With Plasma Cell Disorders (PCD's)

NCT03717844 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 2000

Last updated 2025-11-20

No results posted yet for this study

Summary

The primary purpose of this protocol is to create a registry of patients with plasma cell disorders (PCDs), including for example the cancer multiple myeloma (MM), who complete the assessment, previously known as a "geriatric assessment," as is outlined in this protocol. Secondary objectives include measuring the response rate to participation of patients in this study, assessing patient satisfaction with the questionnaire, and gathering information that would lend support for future research into these types of assessments in patients with PCDs. Additionally the study offers an optional blood draw to look at a genetic marker of aging called p16INK4a (IRB 15-1899, IRB 15-0244).

Conditions

  • Multiple Myeloma
  • Amyloidosis
  • Cryoglobulinemia
  • Castleman's Disease
  • Light Chain Deposition Disease
  • Heavy Chain Deposition Disease
  • Polyneuropathy Organomegaly Endocrinopathy Monoclonal Gammopathy and Skin Changes
  • Smoldering Multiple Myeloma
  • Plasma Cell Leukemia

Sponsors & Collaborators

  • UNC Lineberger Comprehensive Cancer Center

    lead OTHER

Principal Investigators

  • Sascha Tuchman, MD · UNC Lineberger Comprehensive Cancer Center

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-02-09
Primary Completion
2028-02-29
Completion
2029-02-28

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03717844 on ClinicalTrials.gov